Media reports suggest FDA commissioner Marty Makary’s time at FDA may be limited due to White House tension over his management of the agency.
Pharmaceutical advertising experts react to FDA’s dramatically altered enforcement approach toward prescription drug promotion since last fall.
Media reports suggest FDA commissioner Marty Makary’s time at FDA may be limited due to White House tension over his management of the agency.
Pharmaceutical advertising experts react to FDA’s dramatically altered enforcement approach toward prescription drug promotion since last fall.
CBER acting director Katherine Szarama discusses an expansive vision for the biologics center during remarks at the Food and Drug Law Institute’s annual conference in Washington, DC 5/6, emphasizing regulatory flexibility, scientific rigor and increased engagement with industry.
Sanofi asks FDA to remove its Type 1 diabetes therapy Tzield from the agency’s National Priority Voucher review program following an internal disagreement over the drug’s supplemental application.
